Tag Archives: Zhejiang Huahai Pharmaceutical

Almirall Strengthens China Innovation Strategy with New Biopharma Collaboration Focused on Dermatology Treatments

(IN BRIEF) Almirall has signed a collaboration and licensing agreement with Shanghai Huaota Biopharmaceutical, a subsidiary of Zhejiang Huahai Pharmaceutical, to develop a monoclonal antibody candidate for multiple indications including medical dermatology, with Huaota leading early research and initial clinical … Read the full press release